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A B S T R A C T
Accumulating evidence suggests that glutamate, as one of the most important excitatory
neurotransmitters in the brain, plays a key role in drug addiction including opioid addiction. There
is substantial evidence for glutamatergic projections into mesocorticolimbic dopaminergic neurons,
which are associatedwith opioid psychological dependence and are also the key regions of enhancement
effect. Glutamate may be involved in the process of opioid addiction not only by acting on its ionotropic
and metabotropic glutamate receptors that activate several signal transduction pathways, but also by
interacting with other neurotransmitters or neuropeptides such as opioids, dopamine, g-aminobutyric
acid and substance P in the mesocorticolimbic dopaminergic regions. Studies on the role of glutamate
and its receptors in opioid addiction will provide a new strategy for the exploitation of drugs for the
treatment of opioid addiction.
 2009 Elsevier Ltd. All rights reserved.
* Corresponding author. Tel.: +86 29 82655171; fax: +86 29 82656364.
E-mail address: zhaoy502@mail.xjtu.edu.cn (Y. Zhao).
Contents lists available at ScienceDirect
Neuroscience and Biobehavioral Reviews
journal homepage: www.e lsev ier .com/ locate /neubiorev
0149-7634/$ – see front matter  2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neubiorev.2009.02.005
1. Introduction
Drug addiction is a kind of chronic relapsing brain disease
characterized by the loss of control over drug intake, repeated
unsuccessful attempts at quitting or reducing drug use, continued
drug use despite negative consequences, reduction in engagement
in social, occupational and recreational activities in lieu of drug-
seeking or self-administration behavior, and the emergence of
symptoms of tolerance or withdrawal (American Psychiatric
Association, 1994; Koob and Nestler, 1997; Koob et al., 1998,
2004; Gass and Olive, 2008). Some addictive drugs such as opioid,
cocaine, cannabinoids, heroin, amphetamine and nicotine can
produce physical and psychological dependence (Dackis and Gold,
1985; Koob, 1992; Di Chiara, 1995; Wise, 1996; Manzanares et al.,
1999). Although opioids are useful analgesics for clinical use,major
problems associated with the chronic use of opioids are tolerance
and dependence. In addition, long-term use of opioids can lead to
serious physical and psychological dependence, limiting the usage
of opioids and causing an adverse impact on the society (Ree et al.,
1999). Therefore, research on the neurobiological mechanism and
treatments of opioid dependence have been vigorous.
Since all addictive drugs facilitate dopamine (DA) transmission,
determining the role of DA has been the predominant focus of
biomedical research in addiction for the past 20 years (Kalivas,
2004). Recently, accumulating evidence indicates that glutamate
plays an important role in drug addiction especially in latest 5
years (Tzschentke and Schmidt, 2003; Gass and Olive, 2008).
Glutamate is one of the most abundant excitatory neurotransmit-
ters in the brain, mediating as much as 70% of the synaptic
transmission within the central nervous system (Fonnum, 1984;
Cotman et al., 1987; Headley and Grillner, 1990; Gass and Olive,
2008). There are glutamatergic projections and/or neurons
expressing glutamate receptors in some regions of the brain,
including the mesocorticolimbic dopaminergic regions (Heimer
et al., 1997; Wolf, 1998; Groenewegen et al., 1999; Geisler et al.,
2007; Kalivas and O’Brien, 2008), which provide an anatomical
basis for the role of glutamate in addiction.
Drug addiction is a complex process. Interaction of many brain
nuclei with neurotransmitters or neuropeptides constitutes a
neural network, which affects the intracellular signal transduction
and is involved in drug addiction including opioid addiction (De
Vries and Shippenberg, 2002; Kalivas, 2004; Wang et al., 2005).
Many brain regions are involved in the opioid addiction including
locus ceruleus, periaqueductal gray, medial thalamus, hypothala-
mus, amygdala (AMY), globus pallidus, nucleus raphe magnus,
gigantocellular reticular nucleus, ventral tegmental area (VTA),
nucleus accumbens (NAc) and substantia nigra (Temple and Zukin,
1987; Nestler and Aghajanian, 1997; Ivanov and Aston-Jones,
2001; Koob, 2003). Among these brain regions, the VTA and NAc,
important components of mesocorticolimbic dopaminergic
regions, are prominent regions to opioid psychological dependence
and also thought to serve as key regions for mediating reinforce-
ment processes (Harris and Aston-Jones, 1994; Grant et al., 1996;
De Vries and Shippenberg, 2002; Spanagel and Weiss, 2002). This
review will summarize recent research progress on the role and
mechanism of glutamate and its receptors in the mesocortico-
limbic dopaminergic regions in opioid addiction.
2. Anatomy of mesocorticolimbic dopaminergic regions
Mesocorticolimbic dopaminergic pathway is composed of VTA
dopaminergic neurons and its projections, the NAc, AMY and the
medial prefrontal cortex (mPFC), in which the VTA and NAc are the
important nuclei involved in a variety of reward effects (Kalivas,
1993; White, 1996; Bjorklund and Dunnett, 2007). When the VTA,
NAc and central or lateral nucleus of amygdala were lesioned with
a DC current, morphine-induced conditioned place preference
(CPP) can be inhibited (Wang et al., 2002). Morphological study
showed that the both volume and number of neurons in the VTA
and NAc in morphine withdrawal rats decreased (Spiga et al.,
2003). There are also evidence that indicates drug-seeking in
morphine-dependent rats and heroin-induced self-administration
are related to the electrical activities of DA neurons in the VTA and
NAc (Chang et al., 1997; Kiyatkin and Rebee, 2001). The DA level in
the VTA and NAc decreased in morphine withdrawal rats, while
increased in morphine-dependent rats during drug-seeking
(Acquas and Di Chiara, 1992; Herz et al., 1992; Shaham et al.,
1996). These results indicate that the mesocorticolimbic dopami-
nergic regions play important roles in the development of
morphine dependence and during withdrawal.
DA neurons are abundant in the VTA (A10), receiving afferent
fiber projections from the cortex, thalamus, striatum, limbic
system and the brain stem. They also project widely to NAc, mPFC,
piriform cortex, hippocampus, entorhinal cortex, amygdala, hallux
rigidus and brain stem (including locus coeruleus, parabrachial
nucleus and nuclei of median raphe), etc. Not only dopaminergic
neurons (Fallon and Moore, 1978; Swanson, 1982; Margolis et al.,
2006) but also GABAergic and glutamatergic neurons are
cytochemically identified in the VTA (Van Bockstaele and Pickel,
1995; Carr and Sesack, 2000; Margolis et al., 2006; Yamaguchi
et al., 2007). It has also been shown that glutamate can be released
by some VTA neurons (Chuhma et al., 2004; Lavin et al., 2005;
Fields et al., 2007).
The NAc contains three functionally distinct subcompartments,
termed as the shell, core and rostral column based on anatomical
and biochemical differences (Jongen-Relo et al., 1993, 1994; Voorn
et al., 1994; Meredith et al., 1996). The shell region of NAc mainly
received dopaminergic projections from the VTA, while the core
region of NAcmainly received excitatory glutamatergic projections
from amygdala and hippocampus (Kelley et al., 1982; Swanson,
1982; Phillipson and Griffiths, 1985; Groenewegen et al., 1987).
Most of the neurons in NAc are GABAergic (O’Donnell and Grace,
1993; Pennartz et al., 1994). Within the NAc, the core subcompart-
ment has the strongest association with drug-seeking (Di Ciano
et al., 2001; Everitt et al., 2001). There are two categories of
adaptation in glutamate transmission in the NAc: one of which
promotes presynaptic glutamate release and the other alters
postsynaptic responsiveness to released glutamate. It is proposed
that the glutamatergic projection from the mPFC to the NAc is a
final common pathway for eliciting drug-seeking behaviors
(Kalivas and Volkow, 2007).
The major dopaminergic, glutamatergic and GABAergic
efferent and afferent projections in mesocorticolimbic dopami-
nergic pathway including VTA, NAc, mPFC and AMY are shown
in Fig. 1.
3. Types of glutamate receptors
Glutamate is one of the most abundant excitatory neurotrans-
mitters in the central nervous system. Once released into the
synaptic cleft, glutamate can bind to its receptors and exert its
effect. According to pharmacological and molecular biological
classification, glutamate receptors can be divided into two
categories, ionotropic glutamate receptors (iGluRs) and metabo-
tropic glutamate receptors (mGluRs).
3.1. Ionotropic glutamate receptors
Ionotropic glutamate receptors are ligand-gated ion channels
and are divided into three subtypes: N-methyl-D-aspartic acid
(NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic
acid (AMPA) and kainic acid (KA). The latter two are also referred
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to non-NMDA receptors (Monaghan et al., 1989; Young and Fagg,
1990; Seeburg, 1993).
NMDA receptors are heterotetrameric protein complexes that
form ligand-gated ion channels composed of at least one basic
subunit NR1 and regulating subunits NR2 (Dingledine et al., 1999;
Stephenson, 2006; Paoletti and Neyton, 2007). NR1 subunit is the
common subunit while NR2 subunit determines the pharmaco-
logical specificity of the NMDA receptor. There are four types of
NR2 subunits named as NR2A, NR2B, NR2C and NR2D (Monyer
et al., 1992; Nakanishi, 1992). Recently, two newmembers of gene
families that code NMDA receptor subunits were cloned and
named as NR3A and NR3B. They may be involved in the
composition of NMDA receptors (Sucher et al., 1996; Myers
et al., 1999; Madden, 2002). NMDA receptors are coupled with ion
channels including sodium ions, potassium ions and calcium ions.
These receptors induce excitatory postsynaptic potential (EPSP).
Endogenous agonists of the NMDA receptors are glutamate,
aspartate and quinaldinic acid. The activity of NMDA receptors
is regulated not only by the endogenous and exogenous agonists
but also by the binding position of ions and molecules such as
Mg2+, Zn2+, H+, glycine and polyamine.
AMPA receptors are heterotetrameric protein complexes that
form ligand-gated ion channels composed of various subunits
termed as GluR1–4 (also termed as GluRA–D) and GluRd1 and 2
(Dingledine et al., 1999). Kainic acid (kainate, KA) receptors are
tetrameric protein complexes that form ligand-gated ion channels
composed of various subunits. These subunits are termed as
GluR5–7 and KA1 and 2 (Kenny and Markou, 2004). Like NMDA
receptors, AMPA and KA receptors are permeable to Na+ and K+
ions and are able to trigger EPSP.
3.2. Metabotropic glutamate receptors
The mGluRs are G-protein-coupled receptors. Besides having
the same sequence characteristics of seven transmembrane
regions, these receptors have no homology with other G-
protein-coupled receptors. According to sequence similarities,
priorities of agonists and the intracellular signal transduction
pathway, eight kinds of mGluRs can be divided into three groups (I,
II and III; Schoepp et al., 1990; Conn and Desai, 1991; Miller, 1994;
Pin and Duvoisin, 1995; Conn and Pin, 1997). Group I mGluRs
(mGluR1 and 5) are predominately located postsynaptically and
couple to Gq proteins. They mainly hydrolyze inositol phosphate
(PI) into intracellular second messengers diacylglycerol and 1,4,5-
inositol trisphosphate (IP3) through the activation of phospholi-
pase C (Conn and Pin, 1997; Hermans and Challiss, 2001; Coutinho
and Knopfel, 2002). Group ImGluRs also can couple to intracellular
Homer proteins, possibly through a Homer-phosphatidylinositol
3-kinase (PI3K) enhancer adaptor complex (Xiao et al., 2000; Rong
et al., 2003). Group II mGluRs (mGlu2 and 3) are found both pre-
and postsynaptically and group III mGluRs (mGlu4, 6, 7 and 8) are
predominately located presynaptically. Both of them couple to Gi/o
proteins to negatively regulate the activity of adenylyl cyclase (AC)
and decrease the content of cAMP (Schoepp, 2001; Mudo et al.,
2007; Gass and Olive, 2008). The mGluRs can also promote cGMP
production, activation of phospholipase D and the release of
arachidonic acid (Conn and Pin, 1997; Madden, 2002; Pin and
Acher, 2002; Jingami et al., 2003).
4. The role of glutamate and its receptor in opioid addiction
It is known that certain glutamatergic projection could be
impacted by addictive drugs. Data indicate that the activation of
glutamatergic efferent fibers from the amygdala and prefrontal
cortex is critical in the expression of addictive behaviors (Pierce
and Kalivas, 1997; Goldstein and Volkow, 2002; McLaughlin and
See, 2003; See et al., 2003; Kalivas, 2004; Kalivas et al., 2009). The
alteration of glutamate-mediated transmission, especially the
increase of glutamatergic transmission in the NAc may promote
the seeking and relapse from abused drugs (Zhu et al., 1998;
Watanabe et al., 2002; Kenny and Markou, 2004; Paul and Athina,
2004). Suaud-Chagny et al. (1992) reported that microinjection of
glutamate into the VTA can increase exploratory motor behaviors
and the release of DA in NAc and mPFC. These results suggest that
glutamate plays an important role in opioids dependence.
4.1. The role of iGluRs in opioid addiction
Gudehithlu et al. (1994) first reported the change of NMDA
receptors in rat brain following long-term treatment with
morphine. Then it was shown that the expression of NMDA
receptors was upregulated in morphine-dependent rat brains
(Koyuncuoglu et al., 1999). Recently, more studies showed that
glutamatergic signal transduction can regulate drug effects,
resulting in drug tolerance and dependence, including the
tolerance and dependence of opioids. Glutamatergic afferents
play a key role in regulating the firing of the VTA neurons.
Activation of glutamatergic afferents and the VTA infusion of
glutamate receptor agonists increase the firing rates of dopami-
nergic neurons and induce burst firing in vivo (Grace and Bunney,
1984; Chergui et al., 1993; Murase et al., 1993). It was also
demonstrated that MK801, an NMDA receptor antagonist,
completely blocked the withdrawal symptoms induced by
glutamate and naloxone (Tokuyama et al., 1996, 2001). MK-801
can also decrease morphine dependence, which may be related to
the downregulation of NMDA receptors (Gudehithlu et al., 1994;
Koyuncuoglu et al., 1999). Western blot and microdialysis results
showed that chronic intermittent use of morphine, cocaine and
other addictive drugs can increase the level of glutamate in the
VTA, upregulating the expression of AMPA receptor subtypes
GluR1 and NMDAR1 in the VTA (Fitzgerald et al., 1996; Kalivas and
Duffy, 1998). Co-application of opioids and NMDA receptor
competitive or non-competitive antagonists can block the pain
tolerance and physical dependence of opioid and the drug-seeking
behaviors (Nestler et al., 2001). Bisaga et al. (2001) indicated that
glutamatergic signal transduction mediated by NMDA receptors
was involved in the formation and maintenance of morphine
Fig. 1. Major nucleuses and efferent and afferent projections in mesocorticolimbic
dopaminergic pathway. Dopaminergic efferent and afferent are shown in hollow
arrow; glutamatergic efferent and afferent are shown in black arrow; GABAergic
efferent and afferent are shown in arrowwith dash line. Circlemeans the neurons in
VTA are mainly identified as dopaminergic neurons and the hexagon means the
neurons in NAc are mainly identified as GABAergic and some peptidergic neurons.
VTA: ventral tegmental area; NAc: nucleus accumbens; AMY: amygdala; mPFC:
medial prefrontal cortex.
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dependence in human. It was also reported that MK-801 injected
into the VTA reduced the morphine-induced CPP, which suggested
that ionotropic glutamate receptors in the VTA were involved in
the psychological dependence of opioids (Popik and Kolasiewicz,
1999). Our recent studies found that microinjection of NMDA
receptor antagonist MK-801 or non-NMDA receptor antagonist
DNQX into the VTA partly attenuated morphine withdrawal
symptoms induced by naloxone, suggesting that the NMDA and
non-NMDA receptors in the VTA are involved in morphine
withdrawal process (H.L. Wang et al., 2004). Moreover, systemic
and intracerebroventricular injections of NMDA receptor antago-
nists (MK-801, memantine and dextromethorphan, etc.) and non-
NMDA receptor antagonists (DNQX, CNQX, LY293558 and
LY215490) prevented some morphine withdrawal symptoms in
rats (Fundytus and Coderre, 1994; Rasmussen, 1995; Manning
et al., 1996; Bristow et al., 1997; Popik et al., 1998). Microinjection
of ionotropic glutamate receptor antagonists MK-801 or DNQX
into the VTA attenuated the reinforcement effect in heroin
addiction (Xi and Stein, 2002b). Chronic intermittent injection of
escalating doses of morphine is accompanied by ultrastructural
plasticity of GluR1 in neurons that are responsive to glutamate,
activation of DA-induced D1 dopamine receptor in the NAc shell,
and activation of neurons capable of responding to glutamate but
not to D1 dopamine receptor stimulation in the NAc core (Glass
et al., 2008). These results indicate that glutamate released in the
central nervous system plays an important role in opioid with-
drawal behaviors and that the iGluRs are involved in the process.
4.2. The role of mGluRs in opioid addiction
Metabotropic glutamate receptors, which mediate slow gluta-
mate neurotransmission, are located throughout the limbic and
cortical brain regions implicated in drug addiction. There is
significant pharmacological and behavioral evidence that group I
mGluRs are widely distributed in the projection neurons and
intermediate neurons in the shell and core of NAc, providing the
morphological evidence for their regulation and therapic effects in
reward-related behaviors and drug addiction (Mitrano and Smith,
2007; Mitrano et al., 2008). Palucha et al. (2004) found that 3-[(2-
methyl-1,3-thiazol-4-yl)ethynyl] pyridine (MTEP), an mGluR5
antagonist, dose-dependently inhibited morphine withdrawal
symptoms induced by naloxone. DA and glutamate play critical
roles in the induction of LTP in the NAc through the activation of D1
dopamine receptors and group I mGluRs (Schotanus and Chergui,
2008). It was reported that the number and function of group II
mGluRs upregulated the formation of opioids withdrawal. Group II
mGluRs (mGluR2 and mGluR3) were involved in the negative
regulation in the brain reward circuit and the formation of
conditional offensive responses in drug dependence and with-
drawal. LY379268, the group II mGluRs agonist, reduced seeking
behaviors induced by cocaine (Weiss and Baptista, 2003; Peters
and Kalivas, 2006). Agonists of mGlu2/3 receptor prevent the
reinstatement of drug-seeking and drug-taking behaviors after a
period of abstinence (Markou, 2007). Agonists of group II mGluRs
inhibited morphine withdrawal behaviors in 7-, 14- and 21-day-
old rats (Zhu and Barr, 2004). The mGlu2/3 receptors in the NAc
increased at days 1, 3, and 14 of morphine withdrawal (Modafferi
et al., 2008). However, there were some conflicting reports. For
instance, chronic application of cocaine decreased the function of
group II mGluRs in the NAc (Robbe, 2002). Thus, the role of group II
mGluRs in drug dependence was more complicated than
previously thought (Kenny and Markou, 2004). Recently, it was
reported that group III mGluR7 was implicated in many
neurological and psychiatric diseases, including drug addiction.
Systemic or intra-NAc administration of the mGluR7 allosteric
agonist AMN082 dose-dependently lowered NAc extracellular
GABA and increased extracellular glutamate, and such effects were
blocked by (R,S)-alpha-methylserine-O-phosphate (MSOP), a
group III mGluR antagonist (Li et al., 2008). The mGluR8 mRNA
levels were increased in the caudate putamen and NAc 1 day after
the discontinuation of amphetamine treatments and sustained up
to 21 days of withdrawal (Parelkar andWang, 2008). However, the
role of group III mGluRs in drug dependence is still not well
investigated. Further investigation is required to fully understand
the role of mGluRs in the pathological process of drug addiction.
5. The signal transduction pathways of glutamate receptor in
opioid addiction
5.1. Activation of NMDA–Ca2+–NO–cGMP signal transduction
pathway
It was reported that the NMDA–Ca2+–NO–cGMP pathway is
involved in maintaining the excitability of neurons and plays an
important role in opioid addiction and withdrawal (Elliot et al.,
1995; Lizasoain et al., 1996; Noda et al., 1996; Vaupel et al., 1997).
Nitric oxide synthase (NOS) inhibitor L-NAME aswell as the soluble
guanylate cyclase inhibitor methylene blue was found to
significantly attenuate the naloxone-induced withdrawal contrac-
ture in guinea pig ileum. In addition, nitric oxide (NO) precursor
and NO donors were able to reverse the effect of L-NAME. This
effect also demonstrated that the competitive NMDA receptor
antagonist AP-5 potently reduced the amplitude of naloxone-
induced contracture in the samemodel, an effect that was reversed
by co-administration of the excitatory amino acid L-glutamate
(Gabra et al., 2005). In this pathway, Ca2+ is the bridge between
NMDA receptor and NO. Repeated application of opioid can
activate NMDA receptors, subsequently activating the phospha-
tidylinositol pathway and increasing the release of Ca2+. Ca2+ and
calmodulin (CaM) combine to activate the Ca2+/CaM complex and
NOS, resulting in the increase of NO. NO, which acts as a reverse
regulator, can increase the concentration of second messenger
cGMP by activating soluble guanylate cyclase. cGMP, an important
intracellular second messenger, can directly regulate ion channels,
affect the cGMP-dependent protein kinase, or change the cAMP
content through phosphodiesterase, leading to withdrawal symp-
toms (Bredt and Snyder, 1992; Buccafusco et al., 1995; Kotecha and
MacDonald, 2003). In addition, NO increases the release of
glutamate by facilitating the presynaptic NMDA receptors to form
a positive feedback loop, contributing to opioid dependence and
withdrawal.
5.2. Translocation of protein kinase C
Some studies suggest that NMDA enhances Ca2+ influx through
receptor-operated Ca2+ channels, increasing intracellular calcium
concentration and thereby inducing the translocation of protein
kinase C (PKC) in guinea pig cerebral synaptoneurosomes and
immature rat hippocampal slices (Etoh et al., 1991a,b). PKC
translocated to cell membrane in superficial layer of spinal cord
during morphine tolerance (Mayer et al., 1995). In addition, the
development of morphine tolerance was related to the subunit of
PKC, the subunits’ concentration which was positively correlated
to the development of morphine tolerance, and intrathecal
injection of MK-801 that blocked the process (Mao et al., 1995).
This evidence suggests that NMDA receptors were involved in the
upregulation of PKC (Narita et al., 1995). Another study found that
the activation of NMDA receptors inhibited the activity of opioid
receptors and that the blockage of NMDA receptors inhibited the
desensitization of opioid receptors (Cai et al., 1997). When
activated by NMDA receptors, the transcription factor PKC
translocated into cell nucleus, subsequently promoting the
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transcription of PKC and phosphorylate G-protein gene family.
Opioid receptor desensitization occurs as a result (Fan et al., 1998).
5.3. Activation of AC–cAMP–CREB pathway
Some studies on the mechanism of morphine addiction
suggested that repeated application of morphine induced change
in cAMP system played important roles in morphine addiction
(Noda et al., 2001). Chronic application of morphine increased the
concentration of cAMP, cAMP-dependent protein kinase and cAMP
response element binding (CREB) protein, thereby activating
transcription and causing dependence and withdrawal symptoms
(Nestler and Aghajanian, 1997). CREB is one of the members of
CREB/ATF families and is also an important nuclear factor
mediating the cAMP pathway and regulating gene transcription.
Several studies showed that G-protein–cAMP–CREB pathway is the
common mechanism of physical and psychological dependence.
Guitart et al. (1992) found that acute application of morphine into
locus coeruleus induced the decrease of CREB phosphorylation. On
the other hand, long-term application of morphine induced the
gradual increase of CREB and triggered a larger increase in the level
of phosphorylation during naloxone-induced withdrawal (Hay-
ward et al., 1990). Opioid-induced reinforcement and dependence
of drugs by opioid receptors, and opioids receptors changed the
cAMP signal transduction system by exciting G-protein or
inhibiting AC. In addition, opioids could activate Ca2+/CaM-
dependent protein kinase (CaMK) and phosphorylate CREB. And
the activation may be involved in the dependence triggered by the
Ca2+–CaM–CaMK–CREB pathway (Wang et al., 1999). Glutamate
receptors, especially NMDA receptors, can induce synaptic
plasticity change of neurons by activating the AC–cAMP–CREB
pathway, and are therefore involved in opioid dependence and
withdrawal (Wang et al., 1999, 2007).
5.4. Activation of MAPK pathway
The subfamilies of mitogen-activated protein kinases (MAPKs)
include extracellular signal-regulated kinases (ERK1 and ERK2), c-
Jun N-terminal kinases (JNK1, JNK2 and JNK3), p38 MAPKs (p38a,
p38b, p38g and p38d), ERK3/4, and ERK5 (Davis, 2000; Chen et al.,
2001; Chang and Karin, 2001; Johnson and Lapadat, 2002; Roux
and Blenis, 2004). In recent years, the understanding of the role of
the MAPK pathway in opioid-induced effects has evolved rapidly
(Li and Chang, 1996; Chuang et al., 1997; Whistler and von
Zastrow, 1999). Increasing evidence shows that cocaine or
amphetamine and other substances of abuse can strongly activate
the ERK pathway in the striatum or other forebrain structures
through signaling mechanisms initiated by the activation of either
DA or glutamate receptors or both (Berhow et al., 1996; Valjent
et al., 2000, 2005; Freeman et al., 2001; Choe et al., 2002; Zhang
et al., 2004; Jenab et al., 2005; Lu et al., 2005; Shi and McGinty,
2006; Tonini et al., 2006). All three subtypes of iGluRs and the three
subgroups of mGluRs seem to consistently modulate the MAPK
pathway in a stimulatory fashion (Wang et al., 2007). The iGluRs,
particularly the NMDA receptor, may also activate the MAPK
pathway through the Ca2+-sensitive Ras guanine nucleotide
releasing factor, Ca2+-sensitive CaMKII and PI3K. Activation of
the Ca2+-permeable NMDA receptors results in an increase in Ca2+
influx. The Ca2+ signals then activate several Ca2+-dependent
kinases to increase ERK phosphorylation. After activation, ERK
translocates to the nucleus and phosphorylate Elk-1 and CREB to
facilitate gene expression (Valjent et al., 2000; Choe et al., 2002;
Radwanska et al., 2005; Shi and McGinty, 2006). The alterations in
the ERK-dependent transcriptional activity are then translated into
molecular mechanisms underlying several types of persistent
behavioral plasticity, such as rewarding response and behavioral
sensitization induced by single or repeated psychostimulant
administration. Blockage of the ERK pathway therefore abolishes
these behavioral responses (Pierce et al., 1999; Valjent et al., 2000,
2005, 2006; Gerdjikov et al., 2004; Lu et al., 2005). AMPA receptors
positively regulate MAPK/ERK phosphorylation (J.Q. Wang et al.,
2004), and Ca2+-sensitive CaMKII and PI3K are the major kinases
that form a pathway between AMPA receptors and ERK (Perkinton
et al., 1999). Activation of KA receptors increased ERK phosphor-
ylation in striatal neurons (Mao et al., 2004). This increase is also
dependent on extracellular Ca2+ ions, but it is currently unclear
whether other factors are involved in the process. The mGluRs can
also activate MAPK pathway, mainly by the activation of tyrosine
kinase receptor through Ca2+ non-sensitive channels (Wang et al.,
2007).
6. The interaction of glutamate and other neurotransmitters in
opioid dependence
6.1. Glutamate and endogenous opioid peptide
Endogenous opioid peptide is one of the most important
neurotransmitters that are involved in opioid dependence. It has
been demonstrated thatm-opioid receptor is widely distributed in
the VTA and the NAc. Opioids bind to endogenous m-opioid
receptor in these regions, activate the reward circuit and induce
the reward effect (McLean et al., 1986; Mansour et al., 1987;
Johnson and North, 1992). It was reported that MK-801, a non-
competitive NMDA receptor antagonist, inhibited the analgesic
tolerance induced by chronic morphine treatment. Pretreatment
with MK-801 can eliminate the withdrawal symptoms in
morphine-dependent mice (Trujillo and Akil, 1991). Studies have
indicated that high concentration of opioid receptor agonists or
antagonists can directly bind to NMDA receptors and share some
characteristics of non-competitive agonists or antagonists of
glutamate receptors (Yamakura et al., 1999). Enkephalin released
by some neurons in the NAc can act on the m- and d- receptor and
regulate the release of glutamate. MK-801 also can inhibit the
downregulation of m-receptor in morphine-dependent rats
(Koyuncuoglu et al., 1999). In addition, studies about the
regulation of glutamate receptor on the opioid receptor have
been reported. Competitive as well as non-competitive NMDA
receptor antagonists enhance morphine’s antinociceptive effect
and prevent the development of morphine tolerance (Wong et al.,
1996). All these studies suggest that there exists the interaction
between glutamate receptors and opioid receptors which jointly
participate in opiate dependence. The mechanism underlying the
interaction is regarded to be postsynaptic. The glutamate receptor
and opioid receptor can be co-expressed in the same neurons.
Opioids can act on its receptor and induce the disinhibition of
interneurons, which causes the release of glutamate and the
activation of glutamate receptors. It is also presumed that opioids
can act on their receptors, decrease the concentration of cAMP by
inhibiting AC through Gi and Gs, and induce the activation of PKC.
The activation of PKC can remove the blockage of Mg2+ on NMDA
receptors and subsequently activates them (Tingley et al., 1997).
6.2. Glutamate and dopamine
It is well known that DA is the key neurotransmitter since most
abused drugs increase its levels. Many pharmacotherapies have
thus targeted this system (Nutt et al., 2003). The content of DA in
the blood of withdrawal rats was significantly higher than that in
normal rats. Microdialysis analysis showed that morphine could
increase the release of DA (Di Chiara and Imperato, 1998). When
drug-taking behaviors were initiated, dopaminergic and glutama-
tergic neurotransmission in the mesocorticolimbic system was
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activated (Tzschentke and Schmidt, 2003). Morphological studies
showed that there existed axon–axon synapses of glutamate and
DA in mPFC, the ventral striatum and the NAc, providing the
morphological evidence for the interaction between glutamate and
DA in the mesocorticolimbic dopaminergic pathway (Bouyer et al.,
1984; Goldman-Rakic, 1999). Anatomical and electrophysiological
evidence indicates that glutamate can be co-released with DA and
induce long-term regulation on the plasticity (Lapish et al., 2006).
Local application of glutamate can enhance the release of DA in the
NAc (Youngren et al., 1993; Svensson et al., 1994). Electrical
stimulation of basolateral amygdala (BLA) nucleus can increase the
level of DA through its glutamatergic projections into the NAc and
this effect can be blocked by perfusing glutamate receptor
antagonists into the NAc (Floresco et al., 1998). Activation of
iGluRs and mGluRs in the VTA increased the exploring behaviors
and the levels of DA in the NAc and themPFC (Suaud-Chagny et al.,
1992; Swanson and Kalivas, 2000). These results suggest that
glutamate can facilitate the release of DA by its receptors and can
be involved in drug dependence and withdrawal processes.
Application of glutamate receptor antagonists attenuated most
of the withdrawal symptoms. In the addicted state, different
dopaminergic projections may be altered differentially, resulting
in an altered DA–glutamate interaction that ultimately leads to
aberrant control over behaviors and compulsive drug-taking
behaviors (Tzschentke and Schmidt, 2003). DA and glutamate
interact in a complex way. Glutamatergic input to the VTA
increases the activity of dopaminergic cells and enhances DA
release in the NAc (Tzschentke and Schmidt, 2000; Tzschentke,
2001). At the level of the NAc, glutamate also facilitates
dopaminergic transmission, presumably by presynaptically influ-
encing DA release (Blaha et al., 1997; Floresco et al., 1998). The DA
releasing effect of glutamate in the NAc may be predominantly
mediated by AMPA (rather than NMDA) receptors (Youngren et al.,
1993). However, some studies found that application of glutamate
receptor antagonists increased the movement enhancement in
withdrawal rats (Narayanan et al., 1995; Kretschmer, 1999;
Ungless et al., 2001). Consistent with the above, studies also
found that microinjection of glutamate receptor antagonist MK-
801 or DNQX into the VTA attenuated most of the morphine
withdrawal symptoms, except the wall-climbing behavior (H.L.
Wang et al., 2004; Wang et al., 2005). The reason for these
phenomena is that there exist some GABAergic neurons in the VTA
and the NAc, which can inhibit the release of DA. Glutamate
receptor antagonists can increase the release of DA by inhibiting
GABA neurons. DA also affects glutamatergic transmission. For
instance, DA modulates glutamatergic signals in the NAc
originating from the amygdala and hippocampus in a manner
consistent with the concept of a gating mechanism or input
selection (Floresco et al., 2001; Tzschentke and Schmidt, 2003).
6.3. Glutamate and g-aminobutyric acid
GABA is an inhibitory neurotransmitter in the central nervous
system. It is involved in opioid dependence and can inhibit
withdrawal symptoms induced by naloxone (Zarrindast and
Mousa-Ahmadi, 1999). The release of GABA and the amplitude
and frequency of inhibitory postsynaptic potentials of GABAergic
neurons increased in morphine withdrawal rats. The activation of
opioid receptors on VTA interneurons inhibited the activities of
GABA neurons and reduced the release of GABA, which caused the
disinhibition of the DA neurons in the VTA and the release of DA in
the NAc, contributing to opioid withdrawal (Bonci and Williams,
1997). Single or chronic exposure tomorphine inhibited the release
of GABA in the NAc. This effect persisted even after the stop of
morphine. The inhibition of baclofen, a GABA agonist, on morphine
withdrawal symptoms suggested the involvement of GABA in
morphine dependence and withdrawal (Acquas and Di Chiara,
1992). The reward effect in mice and physical dependence induced
by naloxone was attenuated when GABA transporters were over
expressed (Schoffelmeer et al., 2001; Hu et al., 2003). Application of
GABAB receptor antagonist 2-OH-saclofen alone significantly
increased the extracellular concentration of DA, suggesting that
the DA neurons in the VTA were inhibited tonically by endogenous
GABA (Xi and Stein, 2002a). Microinjection of baclofen into the VTA
activated GABAB receptors and blocked self-administration beha-
viors induced by heroin, DA release in the NAc (Xi and Stein, 1998,
1999) and morphine-induced CPP (Tsuji et al., 1996). It can be
presumed that GABAB receptors in the VTA play a key role in opioid
dependence. Anatomical studies show that NMDA and non-NMDA
receptors are located in the postsynaptic GABAergic projection
neurons. Glutamatergic projections from themPFC connected to the
GABAergic spinous neurons with excitatory synapses (Xi and Stein,
2002a). The balance between excitatory amino acid and the
inhibitory amino acid determines the state and response of neurons.
These results suggest that glutamate activate GABAergic neurons in
the NAc by NMDA or AMPA receptor. The activation of GABAergic
neurons increases the releaseofGABAand inhibit theactivitiesofDA
in the VTA, and finally contribute to the opioid addiction.
6.4. Glutamate and substance P
Substance P (SP) is an important sensory neuropeptide widely
distributed in the central and peripheral nervous system and
peripheral tissues. Morphological studies show that nerve fibers
containing SP connect to DA neurons with synapses in the VTA.
There also exist medium-density bradykinin immune positive
fibers in the NAc (Otsuka and Yoshioka, 1993). It has been reported
that SP in the NAc binding with NK-1 receptor could indirectly
inhibit excitatory synaptic transmission by increasing extracellular
level of DA and adenosine (Kombian et al., 2003). Recent studies
have shown that knockout of preprotachykinin A (PPT-A) can
reduce the number of d-opioid receptors inserted into the surface.
The knockout of this molecule also removed spinal analgesia and
the morphine tolerance mediated by d-opioid receptor, suggesting
that there may exist a direct link between tachykinin and opioid
system through interacting with tachykinin/d-opioid receptors
(Guan et al., 2005). Knockout of NK-1 receptors in mice decreased
CPP score induced by morphine and influenced reward effects of
morphine (Gadd et al., 2003). Behavioral studies have shown that
SP (1–7) and SP (1–11) attenuate opioid reward and a variety of
physical withdrawal symptoms, and that SP (1–7) can significantly
reduce the D2 dopamine receptor transcription in the NAc and
mPFC (Zhou et al., 2003). Microperfusion of SP N-terminal
fragment into the VTA increased the content of DA and the DA
metabolism in the NAc in morphine withdrawal mice, suggesting
that N-terminal peptides of SP could attenuate the morphine
withdrawal symptoms by increasing DA release and its metabo-
lism in the NAc. This mechanism may be related to glutamatergic
transmission (Zhou andNyberg, 2002).Morphological studies have
demonstrated that SP and other neurotransmitters such as Glu and
DA are co-localizated in mesocorticolimbic dopaminergic path-
way, indicating that SP may interact with other neurotransmitters
and that it is involved in drug dependence. Some studies have
shown that SP can enhance the effects of glutamate in the spinal
dorsal horn and induce the wind-up phenomenon, which is
regarded as the mechanism underlying the central sensitization
(Dougherty et al., 1993). Local injection of SP enhanced the
nociceptive behavioral response in spinal cord (Carlton et al., 1998)
and increased the discharge of primary afferent fibers induced by
glutamate (Zhang et al., 2006). Administration of monosodium
glutamate could increase the expression of PPT-A mRNA in
cerebral cortex, amygdala, etc. (Xu et al., 2007). All these results
Y. Guo et al. / Neuroscience and Biobehavioral Reviews 33 (2009) 864–873 869
indicate that there exists interaction between glutamate and SP,
but their exact roles in opioid dependence has yet to be studied.
7. Conclusion
Opioid addiction is a chronically relapsing disorder and the
neural network involved is associatedwith several brain nuclei and
neurotransmitters/neuropeptides. There is evidence that the
mesocorticolimbic dopaminergic regions, especially the VTA and
NAc, are the key regions of opioid psychological dependence.
Historically, research into the neurobiological substances that
underlie the drug addiction has focused on the DA system. In the
latest 5 years, more attention has focused on the role of glutamate
and its receptors in mesocorticolimbic dopaminergic regions in
opioid addiction. As a primary excitatory neurotransmitter in the
brain, glutamate can be responsible for development of addictive
behaviors by binding with its iGluRs and mGluRs and involved in
the opioid addiction. The role of iGluRs is well investigated and
antagonists of both NMDA and AMPA receptors attenuate the
withdrawal syndrome of opioid dependence. The role of mGluRs is
still unclear and needs to be further studied. The activations of
several signal transduction pathways including NMDA–Ca2+–NO–
cGMP pathway, AC–cAMP–CREB pathway and MAPK pathway are
involved in the plastic changes induced by glutamate. In addition,
glutamate receptors and other neurotransmitter/neuropeptide
receptors such as opioids, DA, GABA and SP coexisted in the
mesocorticolimbic dopaminergic regions and interact with each
other in opioid addiction. In summary, glutamate and its receptors
are important in opioid addiction, and these findings have
increased our understanding of the neuropathological processes
associatedwith opioid addiction and have provided new targets for
pharmacological approach to the treatment of opioid addiction.
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